• +1-646-491-9876
    • +91-20-67278686

    Search

    Respiratory Syncytial Virus Attachment Glycoprotein Pipeline Review H2 2017

    Respiratory Syncytial Virus Attachment Glycoprotein Pipeline Review H2 2017

    • Report Code ID: RW0001884165
    • Category Pharmaceuticals
    • No. of Pages 40
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2017

    Summary

    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2017, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors. The molecules developed by companies in Phase II and Preclinical stages are 1 and 7 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.

    Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
    - The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
    Agilvax Inc
    Bavarian Nordic A/S
    F. Hoffmann-La Roche Ltd
    MedImmune LLC
    Visterra Inc
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
    AX-14 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bispecific Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MVA-RSV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    respiratory syncytial virus (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    respiratory syncytial virus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    respiratory syncytial virus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRL-3D3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIS-RSV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
    Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
    Featured News & Press Releases
    Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
    Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
    Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
    Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
    Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium
    Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine
    May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
    Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indication, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products under Investigation by Universities/Institutes, H2 2017
    Products under Investigation by Universities/Institutes, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pipeline by Agilvax Inc, H2 2017
    Pipeline by Bavarian Nordic A/S, H2 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Pipeline by MedImmune LLC, H2 2017
    Pipeline by Visterra Inc, H2 2017
    Dormant Projects, H2 2017

    List of Figures

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Agilvax Inc
    Bavarian Nordic A/S
    F. Hoffmann-La Roche Ltd
    MedImmune LLC
    Visterra Inc

    Request for Sample

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-attachment-glycoprotein-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-attachment-glycoprotein-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-attachment-glycoprotein-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments